Ipilimumab (anti-CTLA-4)

Catalog No.A2001 Batch: A200102

Technical Data

CAS No.	477202-00-9
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity	99.28%
Protein concentration	5mg/ml
Endotoxin Level	≤1 EU/mg

Biological Activity

Description

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Targets

CTLA-4 ^[1]
(Cell-free assay)

In vitro

Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.^[1]

In vivo

⁶⁴Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.^[2]

Protocol (Only for Reference)

Cell Assay:	For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.
Animal Study:	AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h) Dosages:~1 mg/mL Administration:i.v.^[2]

Cell Assay:

For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.

Animal Study:

AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model
Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h)
Dosages:~1 mg/mL
Administration:i.v.^[2]

References	[1] Kim CG, et al. J Immunother Cancer. 2021 Dec;9(12):e002780. [2] Ehlerding EB, et al. Mol Pharm. 2017 May 1;14(5):1782-1789.

References

Customer Product Validation

Selleck's Ipilimumab (anti-CTLA-4) has been cited by 16 publications

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy [ Cancer Cell, 2024, S1535-6108(24)00080-1]	PubMed: 38518774
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145]	PubMed: 37190054
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145]	PubMed: 37190054
Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer [ Cancers (Basel), 2023, 16(1)80]	PubMed: 38201508
Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma [ Front Immunol, 2022, 13:925633]	PubMed: 36091050
A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer [ Cancers (Basel), 2022, 14(12)2895]	PubMed: 35740561
Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research [ Sci Rep, 2022, 12(1):13865]	PubMed: 35974123
Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications [ Ann Surg Oncol, 2022, 29(12):7354-7367]	PubMed: 35780216
Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study [ Clin Cancer Res, 2021, clincanres.0982.2021]	PubMed: 34210684
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer [ J Immunother Cancer, 2021, 9(12)e002780]	PubMed: 34907028

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.